Doctor of Medicine, Chief Physician. After obtaining a doctorate in oncology from Peking University Health Science Center in 2008, Dr. [Name] has been working in the Department of Hepatobiliary and Pancreatic Surgery at Peking University Cancer Hospital. With long-term dedication to frontline clinical practice, Dr. [Name] possesses extensive experience in the diagnosis, surgical resection, perioperative comprehensive treatment, and clinical research of metastatic and primary liver cancer, as well as benign and malignant pancreatic tumors. In recent years, Dr. [Name] has focused on minimally invasive surgical oncology and the study of postoperative metastasis and recurrence of metastatic and primary liver cancer, and has participated as a principal investigator in two National Natural Science Foundation of China (NSFC) general projects. Professional Affiliations: - Member, Liver Metastasis Group, Colorectal Tumor Professional Committee, Chinese Medical Doctor Association; - Member, Tumor Ablation Treatment Professional Committee, Chinese Anti-Cancer Association; - Member, Tumor Hepatology Professional Committee, Chinese Anti-Cancer Association; - Member, Metastatic Tumor Treatment Branch, China International Exchange and Promotive Association for Medical and Health Care; - Member, Translational Medicine Branch, Chinese Society of Gerontology and Geriatrics. Representative Achievements: 1. Wang HW, X. Yan, L. Wang, M. Zhang, C. Yang, Wei-Liu, K. Jin, Q. Bao, J. Li, K. Wang and B. Xing, Characterization of genomic alterations in chinese colorectal cancer patients with liver metastases, J TRANSL MED 19 (2021), no. 3131. 2. Xu D, Wang H, Bao Q, Jin K, Liu M, Liu W, Yan X, Wang L, Zhang Y, Wang G, Ma Y, Ma Z, Zhang C, Tang J, Wang S, Pang J, Xu T, Wang K, Xing B. The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial. Nat Commun. 2025 Feb 7;16(1):1443. 3. Wang HW, K. Jin, J. Li, K. Wang and B. Xing, Postoperative complications predict poor outcomes only in patients with a low modified clinical score after resection of colorectal liver metastases: a retrospective cohort study, UPDATES SURG 74 (2022), no. 5, 1601-1610. (SCI收录 IF: 2.692, First Author) 4. L. Wang, Wang HW, Y. Cui, M. Liu, K. Jin, D. Xu, K. Wang and B. Xing, Sintilimab plus lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: a phase 2 study, FRONT ONCOL 13 (2023), no. 1115109. 5. Wang HW, L. Wang, K. Jin, Q. Bao, J. Li, K. Wang and B. Xing, The prognostic impact of resection margin status varies according to the genetic and morphological evaluation (game) score for colorectal liver metastasis, J SURG ONCOL 124 (2021), no. 4, 619-626. 6. Wang HW, L. Wang, K. Jin, Q. Bao, J. Li, S. Ge, K. Wang and B. Xing, Impact of age of onset on survival after hepatectomy for patients with colorectal cancer liver metastasis: a real-world single-center experience, CURR ONCOL 29 (2022), no. 11, 8456-8467.